Relay Therapeutics Statistics
Share Statistics
Relay Therapeutics has 167.38M shares outstanding. The number of shares has increased by 31.79% in one year.
| Shares Outstanding | 167.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 22.39% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 123.26M |
| Failed to Deliver (FTD) Shares | 500 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 12.04M, so 7.2% of the outstanding shares have been sold short.
| Short Interest | 12.04M |
| Short % of Shares Out | 7.2% |
| Short % of Float | 9.88% |
| Short Ratio (days to cover) | 8.26 |
Valuation Ratios
The PE ratio is -3.95 and the forward PE ratio is -2.25.
| PE Ratio | -3.95 |
| Forward PE | -2.25 |
| PS Ratio | 52.83 |
| Forward PS | 1288.6 |
| PB Ratio | 1.79 |
| P/FCF Ratio | -4.43 |
| PEG Ratio | n/a |
Enterprise Valuation
Relay Therapeutics Inc. has an Enterprise Value (EV) of 1.40B.
| EV / Earnings | -4.1 |
| EV / Sales | 54.92 |
| EV / EBITDA | -3.75 |
| EV / EBIT | -3.76 |
| EV / FCF | -4.61 |
Financial Position
The company has a current ratio of 25.44, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.44 |
| Quick Ratio | 25.44 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.66 |
| Cash Flow / Debt | -60.5 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.45% and return on capital (ROIC) is -46.31%.
| Return on Equity (ROE) | -0.45% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -46.31% |
| Revenue Per Employee | 86.89K |
| Profits Per Employee | -1.16M |
| Employee Count | 294 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -53.85% in the last 52 weeks. The beta is 1.68, so Relay Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.68 |
| 52-Week Price Change | -53.85% |
| 50-Day Moving Average | 5.66 |
| 200-Day Moving Average | 6.95 |
| Relative Strength Index (RSI) | 44.39 |
| Average Volume (20 Days) | 1.91M |
Income Statement
In the last 12 months, Relay Therapeutics had revenue of $25.55M and earned -$341.97M in profits. Earnings per share was $-2.79.
| Revenue | 25.55M |
| Gross Profit | 20.28M |
| Operating Income | -373.00M |
| Net Income | -341.97M |
| EBITDA | -374.15M |
| EBIT | -373.00M |
| Earnings Per Share (EPS) | -2.79 |
Balance Sheet
The company has $143.74M in cash and $53.47M in debt, giving a net cash position of $90.27M.
| Cash & Cash Equivalents | 143.74M |
| Total Debt | 53.47M |
| Net Cash | 90.27M |
| Retained Earnings | -1.40B |
| Total Assets | 930.12M |
| Working Capital | 818.16M |
Cash Flow
In the last 12 months, operating cash flow was -$300.32M and capital expenditures -$4.13M, giving a free cash flow of -$304.44M.
| Operating Cash Flow | -300.32M |
| Capital Expenditures | -4.13M |
| Free Cash Flow | -304.44M |
| FCF Per Share | -2.48 |
Margins
Gross margin is 79.37%, with operating and profit margins of -1.46K% and -1.34K%.
| Gross Margin | 79.37% |
| Operating Margin | -1.46K% |
| Pretax Margin | -1.34K% |
| Profit Margin | -1.34K% |
| EBITDA Margin | -1.46K% |
| EBIT Margin | -1.46K% |
| FCF Margin | -1.19K% |
Dividends & Yields
RLAY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -59.62% |
| FCF Yield | -38.86% |
Analyst Forecast
The average price target for RLAY is $19, which is 306% higher than the current price. The consensus rating is "Buy".
| Price Target | $19 |
| Price Target Difference | 306% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 2.64 |
| Piotroski F-Score | 2 |